Side Effects and Complications of Shingles
Shingles causes a painful, vesicular rash that typically resolves in 2-4 weeks, but the most significant complication is postherpetic neuralgia (PHN), occurring in 10-18% of patients and representing the primary source of long-term morbidity and reduced quality of life. 1
Primary Disease Manifestations
The acute infection presents with:
- Painful, vesicular, dermatomal rash that is unilateral and confined to a single dermatome 2
- Prodromal symptoms including malaise, headache, low-grade fever, and abnormal skin sensations for 2-3 days before rash onset 3
- The rash progresses from maculopapular to clear vesicles that become cloudy and crust over in 7-10 days 3
- Acute pain during the initial outbreak can be intense 4
Major Complications
Postherpetic Neuralgia (Most Common)
PHN is defined as persistent dermatomal pain lasting longer than 90 days after symptom onset and represents the most debilitating complication 1. This neuropathic pain condition:
- Occurs in approximately 10-18% of shingles patients (roughly 1 in 5) 1, 3
- Significantly impacts quality of life and can be debilitating 4
- Risk increases with age and delayed treatment initiation 5
Neurological Complications
The virus can cause serious neurological sequelae through direct infiltration or hematogenous spread 6:
- Meningitis and encephalitis
- Ventriculitis and myelitis
- Cerebral angiitis
- Cranial and peripheral nerve palsies 2
- Acute polyneuritis
- Myositis 6
Ophthalmic Complications
Other Complications
Treatment-Related Considerations
Antiviral Therapy
The standard antivirals (acyclovir, valacyclovir, famciclovir) are generally well-tolerated 4, 1. Treatment within 72 hours of rash onset reduces severity and complications 5, 3.
Vaccine Side Effects
While the evidence focuses on disease complications rather than vaccine side effects, it notes that:
- Vaccine adverse effects represent one obstacle to vaccination uptake 1
- The recombinant zoster vaccine (RZV/Shingrix) requires 2 doses 2
- Live vaccine (ZVL/Zostavax) is contraindicated in immunocompromised patients due to theoretical risk of serious disease from the attenuated virus 2
Risk Factors for Worse Outcomes
Older adults and immunocompromised individuals face higher risk of both developing shingles and experiencing severe complications 1. Specific high-risk groups include:
- Adults ≥50 years of age
- Patients with cancer, HIV, diabetes mellitus
- Those with rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease
- Patients on immunosuppressant therapy 2, 7
- Women (at increased risk compared to men) 7
Prevention Impact
Vaccination with recombinant zoster vaccine has demonstrated significant reduction in both shingles incidence and PHN in adults over 60 years 4, making prevention the most effective strategy to avoid these complications entirely 2.